Exact Sciences Corp (EXAS) concluded trading on Thursday at a closing price of $43.04, with 3.36 million shares of worth about $144.47 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -26.28% during that period and on March 13, 2025 the price saw a loss of about -7.14%. Currently the company’s common shares owned by public are about 185.62M shares, out of which, 183.01M shares are available for trading.
Stock saw a price change of -7.72% in past 5 days and over the past one month there was a price change of -15.71%. Year-to-date (YTD), EXAS shares are showing a performance of -23.40% which decreased to -29.09% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $40.62 but also hit the highest price of $79.62 during that period. The average intraday trading volume for Exact Sciences Corp shares is 2.17 million. The stock is currently trading -10.51% below its 20-day simple moving average (SMA20), while that difference is down -17.56% for SMA50 and it goes to -22.76% lower than SMA200.
Exact Sciences Corp (NASDAQ: EXAS) currently have 185.62M outstanding shares and institutions hold larger chunk of about 99.53% of that.
The stock has a current market capitalization of $7.99B and its 3Y-monthly beta is at 1.10. It has posted earnings per share of -$5.56 in the same period. It has Quick Ratio of 1.92 while making debt-to-equity ratio of 1.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EXAS, volatility over the week remained 5.43% while standing at 5.09% over the month.
Stock’s fiscal year EPS is expected to rise by 94.58% while it is estimated to increase by 318.32% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by RBC Capital Mkts on March 13, 2025 offering a Sector perform rating for the stock and assigned a target price of $52 to it. Coverage by Barclays stated Exact Sciences Corp (EXAS) stock as an Overweight in their note to investors on January 23, 2025, suggesting a price target of $70 for the stock. On August 28, 2024, Wells Fargo Initiated their recommendations, while on June 27, 2024, Scotiabank Initiated their ratings for the stock with a price target of $70. Stock get a Buy rating from Jefferies on June 03, 2024.
